{"id":"W2094295731","doi":"10.1002/cam4.363","title":"A phase <scp>2</scp>, multicenter, open‐label study of sepantronium bromide (<scp>YM</scp>155) plus docetaxel in patients with stage <scp>III</scp> (unresectable) or stage <scp>IV</scp> melanoma","year":2014,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"Astellas Pharma Global Development; Astellas Pharma","keywords":"Docetaxel; Medicine; Clinical endpoint; Survivin; Melanoma; Phases of clinical research; Internal medicine; Gastroenterology; Oncology; Chemotherapy; Cancer; Cancer research; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001462305,0.002029864,0.002243228,0.0005495745,0.0004625522,0.0007388611,0.0009695676,0.001245206,0.002819542],"category_scores_gemma":[0.00070784,0.0007377766,0.00142821,0.000423053,0.001032541,0.0009261982,0.0003963817,0.002680274,0.0006752702],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008930321,"about_ca_system_score_gemma":0.001904918,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001106228,"about_ca_topic_score_gemma":0.00268725,"domain_scores_codex":[0.9995871,0.0001987378,0.00001980879,0.00007868259,0.00003995117,0.00007579477],"domain_scores_gemma":[0.9993016,0.00009477938,0.0001791596,0.00005687102,0.00003844462,0.0003291365],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7280343,0.1000834,0.006135944,0.0009514432,0.00106663,0.0004069545,0.0003801578,0.002819146,0.07519349,0.0003145361,0.003859699,0.08075424],"study_design_scores_gemma":[0.4499379,0.5362728,0.007607698,0.00002466302,0.0002188419,0.0002153221,0.0000367286,0.0008673891,0.00311058,0.0001164091,0.001563501,0.00002822613],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938361,0.0009704166,0.0005312013,0.0002593116,0.0001052352,0.002723556,0.0005237492,0.00008391635,0.0009665108],"genre_scores_gemma":[0.9824922,0.002020943,0.003140146,0.001208295,0.000340548,0.004982932,0.002325344,0.00004163316,0.003447798],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002819542,"threshold_uncertainty_score":0.009432316,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02586138156546244,"score_gpt":0.309311015578034,"score_spread":0.2834496340125715,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}